Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Abbvie Inc
ABBV
Alternate Symbol(s):
N.ABBV
Healthcare
Biotechnology
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics...
products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, and more. The Company, through Mitokinin, Inc., offers a lead compound, PINK1 activator, designed to address mitochondrial dysfunction.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:ABBV)
New Post
View:
Posts & Comments
Threaded Posts
(11)
•••
Wrywisdom
X
Post by
Wrywisdom
on Aug 10, 2022 3:21pm
Incredible Value. ENTG at about 25% of One Years Revenue
.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for example indicates record first quarter 2022 results:
...more
(4)
•••
zeropointenergy
X
Post by
zeropointenergy
on Oct 06, 2021 7:20am
ONE DRUG PILL WIPES OUT COVID 19!
India's Ivermectin Blackout - Part V: The Secret Revealed ... Sep 27, 2021 · By September 12, 2021, Livemint reported that 34 districts were declared COVID-free
...more
Worldwide Digital Asset-Backed Exchange Traded Products YTD AUM More Than Doubles
posted Dec 07, 2023 9:00am by
Fineqia International Inc.
-
|
"The tide's been rising for BTC-linked products," said Fineqia CEO Bundeep Singh Rangar. "There's renewed confidence amidst a likely approval of BTC Spot ETFs in the U.S. and the pending Bitcoin halving in April ...read more
(33)
•••
plomar2011
X
Post by
plomar2011
on Sep 01, 2021 1:58pm
what was the big drop ?? saw no news
what was the big drop ?? saw no news
(1)
•••
edwardebreen15
X
Post by
edwardebreen15
on Aug 02, 2021 8:42am
Multiple Sclerosis Therapies Market Industry Growth 2026
According to IMARC Group’s latest report, titled “Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, The global multiple sclerosis
...more
(495)
•••
Mil_Man54
X
Post by
Mil_Man54
on Dec 26, 2020 8:13am
Bonvoyage12....Lying Pumper
Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on multiple boards
(0)
•••
MagnetSauce
X
Post by
MagnetSauce
on Sep 18, 2020 10:46am
🥇💊$HUGE FSD PHARMA COVID19 FDA PHASE 2A🥇💊
Good progress takes time don't be fooled by short sellers
...more
(33)
•••
Nonyah
X
Post by
Nonyah
on Aug 09, 2020 10:42am
Dev Tools
Better Development Tools for a New Golden Era of Psychopharmacology https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
(3)
•••
KingTiger
X
Post by
KingTiger
on Jun 26, 2019 2:27pm
khiron will be the canopy growth of south america
Earnings estimates Currently growing building the company but here are the growth estimates :) FY19 -.42 FY20 -.22
...more
(2)
•••
Raw_Blitz
X
Post by
Raw_Blitz
on Oct 03, 2018 2:47pm
My Technical Analysis for ABBVIE !
Feel free to leave a message with some opinion! https://www.tradingview.com/chart/ABBV/sDz8wSFY-ABBVIE-Technical-Analysis/
(0)
•••
Rambo007
X
Post by
Rambo007
on Aug 26, 2018 12:48pm
good video who Diego might pick
https://www.stockhouse.com/companies/bullboard?symbol=c.thc&postid=28517119
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
POET Technologies Issues Letter to Shareholders
Silver is Considered a Safe Haven Asset But the White Metal Has Far More to it Than Meets the Eye
NexOptic Begins Announcing New Team Additions
AI Alchemy: Turning Data into Gold with Artificial Intelligence
Positive PEA Announced for Proposed Lithium Mining Operation in Ontario
Assays of 14.8% Cu over 2.45 Metres at Historic Canadian Copper Mine drives Record Volume
814 gpt Silver Over 1.0 M Within 6 Meters of 435 gpt and 174 gpt Over 22 M at Columba Silver Project
Emperor Metals Intersects Near Surface Mineralization; Building Bulk Tonnage Open Pit Potential at Duquesne West Gold Project in Quebec
New Images for the Passive Seismic Survey Very Promising for the Topaz Helium Project in Minnesota
Learn How a Pharma R&D Company Can De-Risk Your Healthcare Portfolio